AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.
Tekef
0
5
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. competitor Bristol Myers Squibb, in a deal that would value the joint company at roughly $400 billion, the Financial Times reported on Sunday.
It's still unclear whether the deal will come together, but the companies have been discussing a merger over the last few months, sources told the FT.
The merger would be one of the largest in history.
AstraZeneca and Bristol Myers Squibb did not immediately respond to a CNBC request for comment.
Read the complete Financial Times story here.
This is a developing story. Please check back for updates.
WATCH: AstraZeneca CFO: Very confident we will hit $80 billion revenue target
